Fabric Genomics and Genomenon Sign Partnership Agreement to Speed Genomic Interpretation
Partnership will improve access to critical literature content and accelerate patient diagnosis
OAKLAND, Calif. & ANN ARBOR, Mich.—(BUSINESS WIRE)—Fabric Genomics™, a global leader in clinical interpretation of genomic data, and Genomenon®, the leading genomic data search company, announced today that they have entered into a partnership with the goal of further strengthening clinical genomic interpretation and variant classification.
Fabric Genomics speeds and scales genomic interpretation by combining the most advanced AI algorithms with automated workflows, while Genomenon’s literature search engine facilitates comprehensive literature review, which is advantageous for accurate interpretation. The companies have entered into an agreement to integrate and co-market their solutions, announced today during the American Society of Human Genetics conference in San Diego.
Hospitals and labs are able to maximize their diagnostic yield and optimize turnaround time by using the Fabric Enterprise™ analysis platform offered by Fabric Genomics. Starting with raw-sequence data from whole genome, exome or targeted panels, the platform provides efficient workflows for analyzing, interpreting and signing off physician-ready reports. Fabric Enterprise’s intuitive automated scoring and classification system allows easy adoption of American College of Medical Genetics (ACMG) standards and accelerates interpretation with a step-wise, guided assessment of each ACMG criterion.
When clinical laboratory scientists come upon a variant that is not easily classified, they often face a ‘bottleneck’ when scouring the scientific literature. Genomenon’s Mastermind® Genomic Search Engine filters and prioritizes millions of genomic articles for the most useful and meaningful citations, saving scientists hours of search time and improving the chances of finding key genetic information that could be critical for patient diagnosis. The integration between Fabric Enterprise and Mastermind will allow users to see which candidate variants have any related scientific literature entries, with direct access to a prioritized list of relevant articles during variant interpretation and classification.
“Combining Fabric’s algorithmic genomic analysis with Genomenon’s literature search further enhances our approach to scaling genomic interpretation,” said Martin G. Reese, PhD, Fabric Genomics’ President and CEO. “Fabric is committed to providing users with fast and accurate means of identifying clinically actionable variants that can provide a clear patient diagnosis. Integrating Mastermind within our interpretation platform will help our users minimize the manual effort it takes to select and read relevant evidence-based papers.”
“We’re so pleased to join with Fabric Genomics in the effort to reduce the time needed to detect the cause of genetic illness that can be life-threatening,” said Mike Klein, CEO of Genomenon. “By increasing specificity and sensitivity, reducing false negatives and saving valuable time, our search engine is enhancing the adoption of precision medicine as the gold standard. Fabric’s leadership in genomic interpretation makes them the perfect partner in the effort to achieve that goal.”
“Accelerating time to report coupled with the reassurance that we are accessing the most relevant literature for those hard-to-interpret variants is key,” said Shimul Chowdhury, PhD, Clinical Laboratory Director at Rady Children’s Institute for Genomic Medicine in San Diego, which utilizes Fabric Genomics’ genetic interpretation software and also has early access to Genomenon’s search engine. “Having these two products working together will save valuable time and allow faster access to crucial information that can be life-saving for patients.”
About Fabric Genomics
Fabric Genomics is making genomics-driven precision medicine a reality. The company provides clinical-decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bio-informatics, large-scale genomics and clinical diagnostics. To learn more, visit www.fabricgenomics.com and follow us on Twitter, LinkedIn, and Facebook.
Genomenon powers evidence-based genomics for pharmaceutical companies and clinical diagnostic labs. It is the home of the Mastermind Genomic Search Engine, the world’s most comprehensive source of genomic evidence found in published literature.
Mastermind is used by diagnostic labs to accelerate genomic interpretation for Next Generation Sequencing (NGS) of DNA. Genomenon also licenses the Mastermind knowledgebase to pharmaceutical and life science companies to identify and prioritize genomic biomarkers for drug development, drug trial patient identification, and gene panel design.
Genomenon’s unique products and services facilitate the practice of precision medicine with faster, better diagnosis and treatment options for cancer & rare diseases. For more information, visit www.genomenon.com.
Fabric Genomics Charlene Son Rigby, 510-595-0800, ext. 106 firstname.lastname@example.org or Genomenon Candace Chapman, 734-219-5175 email@example.com